REDMOND, Wash., Sept. 24, 2025 – SystImmune, Inc. announced the upcoming presentation of new clinical data on izalontamab brengitecan (iza-bren) and BL-M07D1, two innovative antibody-drug conjugates (ADCs) from its oncology pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. The presentations will highlight the company’s differentiated ADC platform and its potential to redefine treatment paradigms across multiple solid tumor types.
Science Significance
SystImmune’s ADC platform demonstrates a unique multi-target approach, delivering both precision and potency against hard-to-treat cancers.
Iza-bren, a potentially first-in-class EGFR×HER3 bispecific ADC, combines dual receptor blockade with a novel topoisomerase I inhibitor (Topo1i) payload to induce cancer cell death. The data include late-breaking Phase III results comparing iza-bren to chemotherapy in recurrent/metastatic nasopharyngeal carcinoma, as well as global Phase I safety and efficacy findings in non-small cell lung cancer (NSCLC) and other solid tumors.
The second program, BL-M07D1, targets HER2-positive tumors, showcasing promising activity in metastatic breast cancer and gastric cancer, further validating SystImmune’s platform versatility.
Regulatory Significance
The breadth of late-stage clinical data, including pivotal Phase III trial results, strengthens the regulatory trajectory for SystImmune’s pipeline.
The randomized trial of iza-bren in nasopharyngeal carcinoma—conducted in China—could support future global registration filings, while the global Phase I study expands the evidence base required for multinational regulatory submissions. Positive outcomes may expedite Investigational New Drug (IND) advancement and eventual FDA and EMA filings, placing SystImmune on a fast track toward potential first-in-class approvals.
Business Significance
Advertisement
The ESMO data release underscores SystImmune’s rising profile in the competitive ADC market, which is projected to exceed $20 billion by 2030.
Iza-bren is jointly developed with Bristol Myers Squibb (BMS) under an exclusive license agreement outside China, signaling a strong strategic partnership that enhances global commercialization potential. With two differentiated ADCs advancing in pivotal and proof-of-concept trials, SystImmune is positioning itself as a key player in the next wave of oncology biologics, attracting potential investors and strengthening its competitive advantage in multi-specific antibody platforms.
Patients’ Significance
For patients with difficult-to-treat cancers, these ADCs represent new hope for improved outcomes and quality of life.
Iza-bren’s bispecific mechanism targets EGFR and HER3, receptors frequently implicated in aggressive epithelial cancers, while delivering a potent cytotoxic payload directly into tumor cells. Early results show meaningful single-agent activity in ovarian cancer and EGFR-mutated NSCLC, along with synergistic potential in combination regimens such as small cell lung cancer with PD-1 inhibitors.
BL-M07D1, a novel HER2 ADC, has demonstrated encouraging activity in patients with metastatic breast and gastric cancers who have exhausted existing therapies, potentially expanding treatment options for these underserved populations.
Policy Significance
The rapid clinical advancement of multi-specific ADCs highlights the need for adaptive regulatory frameworks to support accelerated approvals in oncology.
As governments and agencies such as the FDA, EMA, and NMPA grapple with evolving cancer therapies, SystImmune’s pipeline reflects the importance of global clinical collaboration and harmonized trial design. The company’s China-led and globally coordinated studies offer a potential model for future cross-border regulatory strategies, ensuring patients worldwide gain timely access to breakthrough treatments.
Transaction Highlights
At the ESMO Congress 2025, SystImmune will unveil a comprehensive portfolio of pivotal and early-phase clinical data that underscore the progress of its antibody-drug conjugate (ADC) platform. Key highlights include late-breaking Phase III results for izalontamab brengitecan (iza-bren) in recurrent or metastatic nasopharyngeal carcinoma, where the bispecific EGFR×HER3 ADC is being compared head-to-head with physician’s choice of chemotherapy. Global Phase I data will further detail iza-bren’s safety and efficacy in non-small cell lung cancer (NSCLC) and other solid tumors, while additional studies will present the ADC’s potential as a monotherapy in ovarian cancer and in combination with the anti-PD-1 antibody serplulimab for extensive-stage small cell lung cancer. SystImmune will also showcase the first clinical findings for BL-M07D1, a novel HER2-targeted ADC, including safety and preliminary efficacy results in patients with metastatic breast cancer and HER2-positive gastric or gastroesophageal junction adenocarcinoma. Together, these presentations illustrate the breadth of SystImmune’s pipeline and the company’s ability to rapidly advance multiple ADC candidates across tumor types and stages of development.
Source: SystImmune, Inc. Press Release
